Victory Capital Management Inc. Has $27.46 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Victory Capital Management Inc. grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 43.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 710,688 shares of the specialty pharmaceutical company’s stock after acquiring an additional 215,874 shares during the quarter. Victory Capital Management Inc. owned 2.21% of Collegium Pharmaceutical worth $27,461,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. lifted its position in Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares during the period. Rubric Capital Management LP lifted its holdings in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after acquiring an additional 499,473 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after acquiring an additional 17,942 shares during the period. Principal Financial Group Inc. increased its stake in Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after acquiring an additional 64,958 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Collegium Pharmaceutical by 8.0% in the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after acquiring an additional 113,300 shares during the period.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $29.58 on Monday. The business’s fifty day moving average is $36.36 and its two-hundred day moving average is $35.01. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a market cap of $953.96 million, a P/E ratio of 12.75 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 52 week low of $24.61 and a 52 week high of $42.29.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright upped their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, Truist Financial upped their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 13.81 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The trade was a 15.13 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.